Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12659
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLouis, William Jen
dc.contributor.authorDrummer, Olaf Hen
dc.contributor.authorHowes, L Gen
dc.date.accessioned2015-05-16T02:23:10Z
dc.date.available2015-05-16T02:23:10Z
dc.date.issued1989-05-16en
dc.identifier.citationClinical and Experimental Hypertension. Part A, Theory and Practice; 11(5-6): 1075-83en
dc.identifier.govdoc2571433en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12659en
dc.description.abstractAntihypertensive drugs that interact with adrenoceptors have certain advantages and disadvantages (on the treatment of hypertension). Alpha-1 antagonists such as prazosin have favorable effects on plasma lipids but may produce excessive postural falls in blood pressure, particularly following the initial dose. Recently developed alpha-1 antagonists (doxazosin, terazosin) have longer durations of action than prazosin, allowing less frequent administration. Beta blockers may be cardioprotective but in contrast to alpha-1 antagonists tend to have adverse effects on plasma lipids. Drugs with combined beta and alpha-1 blocking activity such as labetalol have favorable metabolic effects but postural hypotension remains a problem. Recently developed drugs with different alpha-1/beta blocking ratios that differ from labetalol may prove to be more popular clinically. Several beta blockers with vasodilator activity which is not due to alpha-1 blockade have also been developed. These drugs appear to have favorable metabolic effects similar to drugs with alpha-1 blocking activity, but do not cause postural hypotension.en
dc.language.isoenen
dc.subject.otherAdrenergic alpha-Antagonists.therapeutic useen
dc.subject.otherAdrenergic beta-Antagonists.therapeutic useen
dc.subject.otherAntihypertensive Agents.adverse effects.therapeutic useen
dc.subject.otherHumansen
dc.subject.otherHypertension.blood.complications.drug therapyen
dc.subject.otherLipids.blooden
dc.subject.otherVascular Diseases.etiology.prevention & controlen
dc.subject.otherVasodilator Agents.therapeutic useen
dc.titleAlpha blockers and vasodilating beta blockers--influence on factors involved in the pathogenesis of vascular disease in patients with hypertension.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical and experimental hypertension. Part A, Theory and practiceen
dc.identifier.affiliationDepartment of Clinical Pharmacology & Therapeutics, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages1075-83en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2571433en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.deptClinical Pharmacology and Therapeutics-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Feb 6, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.